Role of Cytosorb in Severe Covid 19 Patients to Combat Cytokine Storm– A Case Series of 3 Patients

Abstract

Purpose: To demonstrate the effect of Cytosorb on reducing the cytokine levels seen due to cytokine storm in severe COVID 19 patients. Material & Methods: COVID 19 patients with severe HRCT scoring and on NIV/ MV were included in the study. The time points considered in our study are D0, D+1, D+3 & D+5, to look for the levels of inflammatory markers post therapy along with the outcome of patients on D+7 in terms of mortality or off NIV/ MV. Results: Statistical significance tested for the reduction in the WHO score value resulted p value of 0.85. The mean baseline value of the inflammatory markers, CRP, D-DIMER & IL 6 were 66.94, 780.67 &144.67 respectively with range 56.5-81, 331-1211 & 124-167 respectively & p values 0.60, 0.95 & 0.18 respectively. 7-day outcome of the study was 100% mortality.

Dexamethasone, dexamethasone + remdesivir in treating moderate to severe COVID-19: retrospective observational cohort study

“…In order to measure the clinical improvement of hospitalized COVID-19 patients, a 9-point scale developed by WHO was deployed in the study.. According to the scale, uninfected patients are scored as 0, ambulatory patients with no limitations in activities as 1, ambulatory patients with limitations in activities as 2, hospitalized patients with mild symptoms and no oxygen requirements as 3, hospitalized patients requiring oxygen through a mask or nasal prongs as 4, hospitalized patients with severe symptoms and requiring non-invasive ventilation or high flow oxygen as 5, patients with intubation or mechanical ventilation as 6, and patients requiring ventilation and additional oxygen support -pressors/renal replacement therapy/extra corporeal membrane oxygenation (ECMO) as 7, and patients who died were scored as 8 [16].…”

Role of Tocilizumab in Combating Cytokine Storm in Moderate & Severe Covid 19 Patients: Retrospective Observational Study

“…Evidences suggest that, blocking the key inflammatory mediator IL 6 in severe COVID 19 reduces the disease severity [16]. According to the scale 9-point ordinary scale of W.H.O., 0 point is given for the patients who are uninfected, 1 for ambulatory patients with no limitations in activities, 2 for ambulatory patients with limitations in activities, 3 for hospitalized mild diseases patients with no oxygen requirements, 4 for hospitalized and requiring oxygen by mask or nasal prongs, 5 for hospitalized severe diseased patients requiring non-invasive ventilation or high flow oxygen, 6 for patients with intubation or mechanical ventilation, 7 for patients requiring ventilation & additional oxygen support-pressors/ RRT/ ECMO & 8 for death patients [17].…”